Double maintains 1 strategies that include DYN - Dyne Therapeutics, Inc.
Current Value
$10.541 Year Return
Current Value
$10.541 Year Return
Yahoo
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit
SeekingAlpha
The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.
SeekingAlpha
RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with stability and specificity. Explore more details here.
Yahoo
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J. Lucera. The awards were approved by the Compensation Committee of Dyne and made as an inducement material to Mr. Lucera’s acceptance of employment with Dy
Yahoo
Erick J. Lucera Erick J. Lucera, Chief Financial Officer (CFO) of Dyne Therapeutics - Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointment of Erick J. Lucera,
Yahoo
- Continued favorable safety profile for DYNE-251 - - DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 - - Potential for Biologics License Application submission for U.S. accelerated approval in early 2026 - WALTHAM, Mass., March 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 52.77% | $5.33B | 0.35% |
PTH | 47.84% | $110.42M | 0.6% |
GNOM | 46.30% | $53.29M | 0.5% |
IBB | 46.30% | $5.92B | 0.45% |
PBE | 45.32% | $233.11M | 0.58% |
IWC | 43.45% | $810.14M | 0.6% |
IWO | 43.18% | $10.88B | 0.24% |
CPRJ | 42.23% | $48.46M | 0.69% |
KJUL | 41.35% | $155.38M | 0.79% |
KAPR | 40.82% | $185.00M | 0.79% |
VTWO | 40.71% | $10.91B | 0.07% |
IWM | 40.48% | $64.21B | 0.19% |
TMSL | 40.25% | $654.90M | 0.55% |
SCHA | 40.05% | $15.95B | 0.04% |
KJAN | 39.97% | $318.03M | 0.79% |
ARKG | 39.88% | $977.87M | 0.75% |
PINK | 39.76% | $141.43M | 0.5% |
CPSJ | 39.62% | $32.78M | 0.69% |
BBH | 39.32% | $368.79M | 0.35% |
NUSC | 39.27% | $1.11B | 0.31% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RILY | 0.01% | $118.02M | -82.78% | 12.80% |
UL | 0.03% | $149.25B | +19.46% | 3.14% |
FMC | -0.06% | $5.27B | -32.78% | 5.48% |
TEF | -0.11% | $26.30B | +6.15% | 6.71% |
KR | -0.11% | $48.98B | +18.78% | 1.86% |
THS | -0.14% | $1.36B | -30.00% | 0.00% |
RVP | 0.18% | $21.06M | -39.87% | 0.00% |
HRL | 0.21% | $17.01B | -11.55% | 3.66% |
SWBI | -0.24% | $410.11M | -46.06% | 5.62% |
CF | -0.24% | $13.01B | -6.22% | 2.55% |
SRRK | 0.37% | $3.04B | +91.48% | 0.00% |
DAR | -0.40% | $4.94B | -31.19% | 0.00% |
MDLZ | -0.40% | $87.77B | -2.74% | 2.69% |
SNY | 0.44% | $135.77B | +14.85% | 3.67% |
UA | -0.45% | $2.56B | -15.24% | 0.00% |
SO | -0.48% | $100.85B | +29.32% | 3.14% |
MNST | 0.48% | $56.95B | +1.35% | 0.00% |
GCT | 0.49% | $560.29M | -53.88% | 0.00% |
BF.B | -0.58% | $16.04B | -33.48% | 2.61% |
IMMP | 0.60% | $256.18M | -28.16% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VRIG | -0.12% | $1.44B | 0.3% |
TLT | 0.21% | $52.32B | 0.15% |
USFR | 0.25% | $18.41B | 0.15% |
SHYD | -0.26% | $319.64M | 0.35% |
LONZ | 0.30% | $941.51M | 0.63% |
AGGH | -0.32% | $313.78M | 0.29% |
TLTW | 0.37% | $1.15B | 0.35% |
BCD | -0.51% | $249.09M | 0.3% |
DBA | 0.56% | $822.16M | 0.93% |
CLOI | 0.61% | $1.02B | 0.4% |
IBTF | 0.62% | $2.24B | 0.07% |
GOVT | 0.92% | $27.12B | 0.05% |
EDV | -0.97% | $3.93B | 0.05% |
BSMW | 0.98% | $100.61M | 0.18% |
VGLT | 0.98% | $9.88B | 0.03% |
SCHQ | 1.00% | $934.09M | 0.03% |
ICLO | 1.12% | $354.53M | 0.2% |
KRBN | 1.15% | $173.49M | 0.85% |
IYK | -1.16% | $1.50B | 0.4% |
CARY | -1.17% | $347.36M | 0.8% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -21.06% | $23.69B | +24.42% | 1.08% |
RPRX | -14.71% | $13.49B | +4.11% | 2.72% |
BG | -13.29% | $10.24B | -25.29% | 3.53% |
SOC | -12.44% | $2.27B | +131.69% | 0.00% |
ADM | -11.79% | $23.05B | -23.00% | 4.19% |
KVUE | -11.42% | $45.83B | +12.95% | 3.39% |
NOC | -9.95% | $74.12B | +8.63% | 1.60% |
BNED | -9.94% | $357.56M | -83.95% | 0.00% |
PEP | -9.86% | $205.64B | -13.32% | 3.60% |
EL | -9.63% | $23.74B | -56.59% | 3.02% |
CHD | -9.26% | $27.09B | +4.83% | 1.03% |
WBA | -9.20% | $9.66B | -42.84% | 6.72% |
HELE | -8.87% | $1.22B | -53.40% | 0.00% |
PGNY | -8.33% | $1.91B | -38.81% | 0.00% |
AEP | -7.98% | $58.35B | +29.22% | 3.34% |
ED | -7.54% | $39.05B | +22.43% | 3.04% |
JKHY | -7.38% | $13.31B | +7.12% | 1.21% |
MOH | -7.13% | $18.02B | -18.51% | 0.00% |
STG | -7.07% | $28.45M | -43.90% | 0.00% |
OXBR | -6.95% | $14.07M | +68.75% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -31.73% | $404.97M | 1.43% |
VIXY | -31.51% | $195.31M | 0.85% |
TAIL | -23.20% | $86.92M | 0.59% |
USDU | -12.60% | $213.46M | 0.5% |
SGOV | -12.54% | $39.39B | 0.09% |
CTA | -11.49% | $963.19M | 0.76% |
UUP | -11.49% | $327.80M | 0.77% |
JMST | -10.52% | $3.55B | 0.18% |
DBE | -9.14% | $54.58M | 0.77% |
TBIL | -8.72% | $5.32B | 0.15% |
SOYB | -8.31% | $25.81M | 0.22% |
KMLM | -8.13% | $222.40M | 0.9% |
USCI | -7.82% | $236.09M | 1.07% |
USO | -7.43% | $1.02B | 0.6% |
COMT | -7.39% | $674.22M | 0.48% |
TPMN | -7.30% | $33.51M | 0.65% |
BNO | -7.02% | $95.40M | 1% |
GSG | -6.83% | $1.04B | 0.75% |
DBO | -6.73% | $197.54M | 0.77% |
FXY | -6.26% | $546.19M | 0.4% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRNX | 46.50% | $3.12B | -27.92% | 0.00% |
RNA | 46.41% | $3.55B | +11.82% | 0.00% |
RVMD | 43.19% | $6.57B | +11.62% | 0.00% |
ROIV | 42.84% | $7.20B | -3.26% | 0.00% |
MRSN | 41.08% | $42.90M | -92.21% | 0.00% |
KYMR | 40.91% | $1.78B | -30.57% | 0.00% |
APGE | 40.59% | $2.22B | -42.57% | 0.00% |
PTCT | 40.31% | $4.02B | +78.24% | 0.00% |
WIX | 40.27% | $9.10B | +18.90% | 0.00% |
JEF | 39.65% | $11.04B | +23.01% | 2.63% |
STOK | 39.50% | $359.62M | -50.70% | 0.00% |
NTLA | 38.31% | $736.01M | -73.88% | 0.00% |
RGNX | 38.28% | $358.12M | -66.79% | 0.00% |
RCKT | 38.14% | $711.22M | -75.04% | 0.00% |
IDYA | 38.06% | $1.43B | -61.48% | 0.00% |
MSA | 37.77% | $5.76B | -23.17% | 1.40% |
ARWR | 37.72% | $1.75B | -54.89% | 0.00% |
BN | 37.55% | $78.54B | +27.24% | 0.63% |
FATE | 37.51% | $90.54M | -88.84% | 0.00% |
ATXS | 36.89% | $301.36M | -60.47% | 0.00% |